We are a non-profit organization dedicated to unlocking the potential of regenerative medicine. Our passion lies in applying cutting-edge technologies to address real-world needs.
427
Lives Served
34
FDA Protocols
$0
Cost to Patients
8
Peer-Reviewed Studies
We are committed to advancing medical knowledge and bridging the gap between scientific discovery and healthcare innovation. By sharing our research findings with the public, policymakers, and other stakeholders, we help drive progress.
Collaboration is key — we partner with governments, nonprofits, academic institutions, and private sector leaders to extend our impact across regenerative medicine.
A patient-first approach — designed in-house, delivered safely, and shared transparently.
01Research Excellence
Our protocols are designed in-house by leading experts, adhering to the highest scientific standards. We prioritize both safety and efficacy, rigorously tracking every step of the process — primarily addressing chronic degenerative diseases considered "incurable."
02Real Impact
As a full-service Clinical Research Organization, we offer comprehensive support — from protocol development to biostatistics programming. Join us in paving the way for the future of regenerative medicine.
Trusted Care
Explore the pathways for accessing cell therapy. Use our resources to navigate the investigational treatment process. Join the participants who have made HBRF a leader in stem cell research and innovation.
Together
It is due to our partner community that we are able to advance our research efforts, drive innovation, and expand our knowledge base — enabling us to deliver cutting-edge solutions and greater value to our stakeholders.
0
FDA Authorized Protocols
Designed in-house by leading experts.
0
Lives Served
Across age groups from 1 to 85.
0B+
Stem Cells Administered
Safely delivered through our protocols.
$0
Cost to Patients
Every study is provided free of charge.
ELSEVIER
01An Intermediate Size Patient Population Expanded Access IND to Evaluate the Efficacy and Safety of autologous HB-adMSCs for the treatment of subjects with Parkinson's disease
Source
Cytotherapy
Date
10/4/2024
DOI 10.1016/J.JCYT.2024.09.004
FRONTIERS
02A Randomized Placebo-Controlled, Double Blinded, Efficacy and Safety Study of Allogeneic HB-adMSCs for the treatment of COVID-19
Source
Frontiers in Medicine
Date
12/21/2023
DOI 10.3389/FMED.2023.1321303
FRONTIERS
03Individual Patient Expanded Access IND of Hope Biosciences Autologous HB-adMSCs for the Treatment of Chronic Spinal Cord Injury (SCI)
Source
Frontiers in Transplantation
Date
12/7/2023
DOI 10.3389/FRTRA.2023.1287508
BMC
04Intermediate Size Expanded Access Protocol Evaluating HB-adMSCs for the Treatment of Post-COVID-19 Syndrome (LongHaulers)
Source
Stem Cell Research & Therapy
Date
10/5/2023
DOI 10.1186/S13287-023-03522-1
FRONTIERS
05Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease
Source
Frontiers in Neurology
Date
9/27/2023
DOI 10.3389/FNEUR.2023.1257080
CLINMED INTERNATIONAL LIBRARY
06Individual Patient Expanded Access Protocol of Autologous HB-adMSCs for the treatment of Cerebral Palsy
Source
International Journal of Stem Cell Research & Therapy
Date
3/29/2023
DOI 10.23937/2469-570X/1410078
ELSEVIER
07Individual Patient Expanded Access IND to evaluate the safety and efficacy of HB-adMSCs for the treatment of Systemic Lupus Erythematosus (SLE)
Source
Journal of Translational Autoimmunity
Date
9/23/2022
DOI 10.1016/J.JTAUTO.2022.100166
BMC
08A phase 1/2a Clinical Trial to assess safety of a single IV infusion of autologous adipose-derived mesenchymal stem cells in adults with active Rheumatoid Arthritis
Source
Stem Cell Research & Therapy
Date
3/3/2022
DOI 10.1186/S13287-022-02763-W
WILEY
09Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial
Source
Parkinson's Disease
Date
13/05/2026
DOI 10.1155/padi/9934417
01 / 09
Now playing
Gordon Bethune
Sponsor and Participant of EA for Parkinson's Disease
Trusted by leading research foundations
A community advancing regenerative medicine.
Every study we design and execute is provided to patients at no cost, thanks to the generous support of our community. To date, we have served 427 patients, free of charge.
Tax-deductible · 501(c)(3)
Hope Biosciences Research Foundation is a registered 501(c)(3) tax-exempt organization, EIN 84-3802908, administered through the Greater Houston Community Foundation.
Sign up to receive hopeful news and updates. Your privacy is important to us, and we do not share your information.
